Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1530/ERC-14-0005 http://scihub22266oqcxt.onion/10.1530/ERC-14-0005 C4170053!4170053!24659480     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocr+Relat+Cancer 2015 ; 22 (1): T1-T17 Nephropedia Template TP {{tp|p=24659480|t=2015. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors |pdf=|usr=}}{{24659480}} gab.com Text The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors JO: Endocr Relat Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24659480 #FOAvip The destruction of proteins via the ubiquitin-proteasome system is a multi-step, complex process involving polyubiquitination of substrate proteins, followed by proteolytic degradation by the macromolecular 26S proteasome complex. Inhibitors of the proteasome promote the accumulation of proteins that are deleterious to cell survival, and represent promising anti-cancer agents. In multiple myeloma and mantle cell lymphoma, treatment with the first generation proteasome inhibitor bortezomib, or the second generation inhibitor carfilzomib, has demonstrated significant therapeutic benefit in humans. This has prompted US FDA approval of these agents and development of additional second generation compounds with improved properties. There is considerable interest in extending the benefits of proteasome inhibitors to the treatment of solid tumor malignancies. Herein we review progress that has been made in the preclinical development and clinical evaluation of different proteasome inhibitors in solid tumors. In addition, we describe several novel approaches that are currently being pursued for the treatment of solid tumors, including drug combinatorial strategies incorporating proteasome inhibitors, and the targeting of components of the ubiquitin-proteasome system that are distinct from the 26S proteasome complex. Twit Text FOAVip The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors ????Endocr Relat Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24659480 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24659480 #FOAvip English Wikipedia <ref>{{Cite pmid|24659480}}</ref> The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors #MMPMID24659480 Johnson DE Endocr Relat Cancer 2015[Feb]; 22 (1): T1-T17 PMID24659480show ga The destruction of proteins via the ubiquitin-proteasome system is a multi-step, complex process involving polyubiquitination of substrate proteins, followed by proteolytic degradation by the macromolecular 26S proteasome complex. Inhibitors of the proteasome promote the accumulation of proteins that are deleterious to cell survival, and represent promising anti-cancer agents. In multiple myeloma and mantle cell lymphoma, treatment with the first generation proteasome inhibitor bortezomib, or the second generation inhibitor carfilzomib, has demonstrated significant therapeutic benefit in humans. This has prompted US FDA approval of these agents and development of additional second generation compounds with improved properties. There is considerable interest in extending the benefits of proteasome inhibitors to the treatment of solid tumor malignancies. Herein we review progress that has been made in the preclinical development and clinical evaluation of different proteasome inhibitors in solid tumors. In addition, we describe several novel approaches that are currently being pursued for the treatment of solid tumors, including drug combinatorial strategies incorporating proteasome inhibitors, and the targeting of components of the ubiquitin-proteasome system that are distinct from the 26S proteasome complex. äThe ubiquitin-proteasome system: opportunities for therapeutic interve(epmc).pdf DeepDyve Pubget Overpricing